Trial Profile

Single Ascending Dose and Repeat Dose Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Sargramostim Administered Subcutaneously, by Intravenous Infusion, or by Inhalation in Healthy Adult Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sargramostim (Primary) ; Sargramostim (Primary) ; Sargramostim (Primary)
Indications Acute hypoxia; Acute radiation syndrome; Alzheimer's disease; Bone marrow disorders; Chronic lymphocytic leukaemia; COVID 2019 infections; Down syndrome; Haematological malignancies; Malignant melanoma; Neutropenia; Pneumococcal infections; Prostate cancer; Pulmonary alveolar proteinosis; Sepsis; Skin cancer; Stem cell mobilisation
Focus Pharmacokinetics
Sponsors Partner Therapeutics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com